Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D5LX
|
|||
| Former ID |
DIB010806
|
|||
| Drug Name |
NKTT-120
|
|||
| Synonyms |
INKT mAb; Natural killer T cell antibody (asthma/COPD/Dermatitis); NKT cell antibody (asthma/COPD/Dermatitis), NKT; Natural killer T cell antibody (asthma/COPD/Dermatitis), NKT Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57.0; ICD-9: 282.6] | Phase 1 | [1], [2] | |
| Company |
Nkt therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin G1k (IgG1k) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01783691) Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Advances in Sickle Cell Therapies in the Hydroxyurea Era. Mol Med. 2014; 20(Suppl 1): S37-S42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.